2[1]Schievink WI. Intracranial aneurysms. N Engl J Med, 1997,336:28 ～40.
3[2]Hong BK, Kwon H M, Lee BK ,et al. Coexpression of cycolooxygenase-2 and matrix metalloproteinases in human aortic atherosclerotic lesions.Yonli Med J ,2000,41:82 ～ 88.
4[3]Thompson RW, Baxter BT. MMP inhibition in abdominal aortic aneurysms. Rationale for a prospective randomized clinical trial. Annals NY Acad Sci, 1999,878:159 ～ 178.
5[4]Cammeliet P. Proteinases in cardiovascular aneurysms and rupture: targets for therapy? J Clin Invest,2000,105:1519 ～ 1520.
6[5]Pyo R, Lee JK, Shipley JM, et al. Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms. J Clin Invest, 2000,105:1641 ～1649.
7[6]Ross R. Cellular and molecular studies of atherogenesis. Atherosclerosis, 1997,131 ( Suppl ): S3 ～ 4.
8[7]Chyatte D, Lewis I. Gelatinase activity and the occurrence of eerebral aneurysms. Stroke, 1997,28:799 ～ 804.
9[8]Brew K, Dinakarpandian D, Nsgase H. Tissue i nhibitors of metalloproteinases: evolution, structure and function. Biochem Biophys Acta,2000,1477:267 ～ 283.
10[9]Bruno G,Todor R, Lewis I, et al. Vascular extracellular matrix remodeling in cerebral aneurysms. J Neurosurg,1998,89:431 ～440.
